Bolt Biotherapeutics, Inc. — Director's Dealing 2021

Feb 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Bolt Biotherapeutics, Inc. (BOLT)
CIK: 0001641281
Period of Report: 2021-02-04

Reporting Person: Schatzman Randall C (Director, Chief Executive Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$2.73	2029-09-06	Common Stock (791185)		Direct
Stock Option (Right to Buy)	$4.34	2030-09-02	Common Stock (100000)		Direct
Stock Option (Right to Buy)	$4.34	2030-09-02	Common Stock (178571)		Direct

Footnotes

F1: 1/4th of the shares subject to the option shall vest on the one (1) year anniversary of July 15, 2019 (the "Vesting Commencement Date"), and 1/48th of the shares shall vest each month thereafter on the same day of the month as the vesting commencement date, subject to the Reporting Person continuing to be a service provider to the Issuer through each such date.

F2: For so long as the Reporting Person continuously provides services to the Issuer (or any subsidiary or parent of the Issuer) as an employee, officer, director, contractor or consultant, through the applicable vesting dates, this option will vest and become exercisable as follows: (a) prior to September 3, 2020 (the "2020 Vesting Commencement Date"), this option will not be vested or exercisable as to any of the shares subject to the option; and (b) following the 2020 Vesting Commencement Date, this option will become vested and exercisable with respect to 1/48th of the shares subject to the option when the Reporting Person completes each month of continuous service following the 2020 Vesting Commencement Date.

F3: For so long as the Reporting Person continuously provides services to the Issuer (or any subsidiary or parent of the Issuer) as an employee, officer, director, contractor or consultant, through the applicable vesting dates, this option will vest and become exercisable as follows: (a) prior to January 15, 2021 (the "2021 Vesting Commencement Date"), this option will not be vested or exercisable as to any of the shares subject to the option; and (b) following the 2021 Vesting Commencement Date, this option will become vested and exercisable with respect to 1/48th of the shares subject to the option when the Reporting Person completes each month of continuous service following the 2021 Vesting Commencement Date.